Jane Street’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Jane Street’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,704	Closed	-$555K	–	12655
2025 Q3	$555K	Buy	+23,704	New	+$545K	﹤0.01%	7630
2025 Q2	–	Sell	-24,891	Closed	-$536K	–	11167
2025 Q1	$536K	Buy	24,891 +1,215	+5%	+$27.6K	﹤0.01%	6733
2024 Q4	$534K	Buy	23,676 +9,123	+63%	+$225K	﹤0.01%	6644
2024 Q3	$390K	Sell	14,553 -6,656	-31%	-$179K	﹤0.01%	7611
2024 Q2	$553K	Buy	+21,209	New	+$545K	﹤0.01%	6860

Other funds holding THNR

CCA

Cravens & Co Advisors Cookeville, Tennessee $154M AUM 17.67% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $117M AUM

Jane Street's THNR Position: Q4 2025 in Review

Jane Street sold out of Amplify Weight Loss Drug & Treatment ETF (THNR) in Q4 2025, closing a stake of 23,704 shares — an estimated $555K sold.

Jane Street first reported a position in THNR in Q2 2024 and held it in 5 quarters. The position peaked at $555K in Q3 2025. 2 funds tracked by Wall St. Rank hold THNR as of Q4 2025.

Jane Street reported no remaining Amplify Weight Loss Drug & Treatment ETF position as of Q4 2025 after selling out during the quarter.
Jane Street sold 23,704 Amplify Weight Loss Drug & Treatment ETF shares in Q4 2025, an estimated $555K.
Jane Street first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q2 2024 and held it in 5 quarters.
Jane Street's Amplify Weight Loss Drug & Treatment ETF position peaked at $555K in Q3 2025.
2 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.